InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (336)	11/5/2002 9:06:55 AM
From: IRWIN JAMES FRANKEL	of 508

The PIV Infergen data appears to be as good or better in producing SVR than Peg-Rebetron. I say "appears" because I do not know the composition of the PIV by genotype. But if there is any substantial genotype 1 group (which should be the case and is supported by some language in the PR) in the study then Infergen is the better drug even when compared to the peyglated versions. That is better than I could have hoped. ij Comparative data: janis7hepc.com See sections Summary of FDA Peg-Intron Hearing and Ribavirin (RBV) Weight Based Dosing

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next